CareDx Announces Board Changes and Executive Compensation Update
Ticker: CDNA · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1217234
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: CDNA
TL;DR
Board shakeup at CareDx: New director elected, audit chair appointed, and CMO gets a new pay deal.
AI Summary
CareDx, Inc. announced on September 6, 2024, a series of significant corporate actions. These include the departure of Director Dr. Robert L. Brush, the election of new Director Dr. David E. R. Sutherland, and the appointment of Dr. Sutherland as Chair of the Audit Committee. Additionally, the company entered into a new compensatory arrangement with its Chief Medical Officer, Dr. John L. Watts.
Why It Matters
Changes in board composition and leadership roles can signal shifts in company strategy or governance, while executive compensation adjustments may reflect performance expectations or retention efforts.
Risk Assessment
Risk Level: medium — Board and executive changes, along with compensation adjustments, can introduce uncertainty regarding future strategic direction and operational stability.
Key Players & Entities
- CareDx, Inc. (company) — Registrant
- Dr. Robert L. Brush (person) — Departing Director
- Dr. David E. R. Sutherland (person) — Newly Elected Director and Audit Committee Chair
- Dr. John L. Watts (person) — Chief Medical Officer
- September 6, 2024 (date) — Date of earliest event reported
FAQ
Who has departed from CareDx's board of directors?
Dr. Robert L. Brush has departed from CareDx's board of directors.
Who has been elected as a new director to CareDx's board?
Dr. David E. R. Sutherland has been elected as a new director to CareDx's board.
What new role has Dr. David E. R. Sutherland taken on?
Dr. David E. R. Sutherland has been appointed as the Chair of the Audit Committee.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 6, 2024.
What is the compensatory arrangement mentioned for the Chief Medical Officer?
The filing indicates that a new compensatory arrangement has been entered into with the Chief Medical Officer, Dr. John L. Watts.
Filing Stats: 1,708 words · 7 min read · ~6 pages · Grade level 10.6 · Accepted 2024-09-12 07:04:00
Key Financial Figures
- $0.001 — nge on which registered) Common Stock, $0.001 Par Value CDNA The Nasdaq Stock Mar
- $575,000 — edy's initial annualized salary will be $575,000, and he will be eligible to receive an
- $100,000 — months of his employment not to exceed $100,000. Mr. Kennedy's employment will be on an
- $2,000,000 — on"), having a grant date fair value of $2,000,000, which option will vest over four years
Filing Documents
- d864562d8k.htm (8-K) — 36KB
- d864562dex101.htm (EX-10.1) — 14KB
- d864562dex102.htm (EX-10.2) — 102KB
- d864562dex103.htm (EX-10.3) — 80KB
- d864562dex991.htm (EX-99.1) — 8KB
- g864562g94b73.jpg (GRAPHIC) — 12KB
- 0001193125-24-217626.txt ( ) — 444KB
- cdna-20240906.xsd (EX-101.SCH) — 3KB
- cdna-20240906_lab.xml (EX-101.LAB) — 18KB
- cdna-20240906_pre.xml (EX-101.PRE) — 11KB
- d864562d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Offer Letter, dated July 27, 2024, between CareDx, Inc. and Keith Kennedy. 10.2 Change of Control and Severance Agreement, dated July 27, 2024, between CareDx, Inc. and Keith Kennedy. 10.3 Confidential Information, Invention Assignment, Non-Competition, and Arbitration Agreement, dated July 27, 2024, between CareDx, Inc. and Keith Kennedy. 99.1 Press release dated September 12, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). - 3 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 12, 2024 CAREDX, INC. By: /s/ John Hanna John Hanna Chief Executive Officer - 4 -